Nature Metabolism

Nature Metabolism

@natmetabolism.nature.com

Nature Metabolism publishes studies that advance our understanding of metabolic and homeostatic processes in physiology and disease. https://www.nature.com/natmetab/

4.9K followers210 following1.7K posts

Nature Metabolism
@natmetabolism.nature.com
dlvr.itGenetic modulation of NAD(P)H homeostasis reveals distinct redox-coupled metabolic vulnerabilitiesNature Metabolism, Published online: 14 October 2026; doi:10.1038/s42255-026-01640-7Using genetically encoded tools that shift the redox equilibrium, the authors identify a link between oxidative and reductive stress, suggesting that simultaneously targeting NAD(P)H homeostasis could be a therapeutic strategy for age-related redox-driven metabolic vulnerabilities.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itA multi-fluid exercise proteomic atlas reveals regulators of health and diseaseNature Metabolism, Published online: 12 October 2026; doi:10.1038/s42255-026-01642-5A single bout of exercise triggers thousands of coordinated protein changes across blood, saliva and urine. By integrating tissue atlases, human genetics and in vivo functional validation, we present a multi-fluid resource that serves as a starting point for prioritizing robust candidate exercise-regulated proteins that might mediate the cardiometabolic health benefits of long-term exercise.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itInhibiting fructose metabolism to treat fatty liverNature Metabolism, Published online: 07 October 2026; doi:10.1038/s42255-026-01627-4In this issue of Nature Metabolism, Koene et al. present evidence that inhibiting fructose metabolism (using a ketohexokinase inhibitor) can improve hepatic steatosis and insulin resistance in individuals who are prediabetic with obesity and metabolic dysfunction-associated steatotic liver disease, supporting further development and testing of fructose inhibitors in metabolic disease.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itMetabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trialNature Metabolism, Published online: 07 October 2026; doi:10.1038/s42255-026-01626-5In a randomized placebo-controlled crossover trial, pharmacological inhibition of ketohexokinase improved hepatic and systemic metabolic health in individuals with MASLD, highlighting fructose metabolism as a promising therapeutic target with benefits extending beyond the liver.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itGenetic modulation of NAD(P)H homeostasis reveals distinct redox-coupled metabolic vulnerabilitiesNature Metabolism, Published online: 14 October 2026; doi:10.1038/s42255-026-01640-7Using genetically encoded tools that shift the redox equilibrium, the authors identify a link between oxidative and reductive stress, suggesting that simultaneously targeting NAD(P)H homeostasis could be a therapeutic strategy for age-related redox-driven metabolic vulnerabilities.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itArginine inhibits a key innate immune signalling hubNature Metabolism, Published online: 06 October 2026; doi:10.1038/s42255-026-01638-1The NLRP3 inflammasome has crucial roles in immunity and disease and is a key target for therapeutic efforts. In this issue of Nature Metabolism, Liu et al. show that l-arginine can inhibit inflammasome activation, highlighting the potential of dietary arginine supplementation as a treatment for NLRP3-related disease.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itA multi-fluid exercise proteomic atlas reveals regulators of health and diseaseNature Metabolism, Published online: 12 October 2026; doi:10.1038/s42255-026-01642-5A single bout of exercise triggers thousands of coordinated protein changes across blood, saliva and urine. By integrating tissue atlases, human genetics and in vivo functional validation, we present a multi-fluid resource that serves as a starting point for prioritizing robust candidate exercise-regulated proteins that might mediate the cardiometabolic health benefits of long-term exercise.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itMetabolic and neural responses to ultraprocessed foods: a randomized, controlled, crossover studyNature Metabolism, Published online: 05 October 2026; doi:10.1038/s42255-026-01619-4In a randomized study in 57 healthy-weight adults, researchers compared nutritionally matched ultraprocessed and non-ultraprocessed meals and found that ultraprocessed foods elicited greater insulin and energy responses, reduced carbohydrate oxidation and altered striatal brain activity linked to food reward despite similar subjective food value.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itSenolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trialNature Metabolism, Published online: 01 October 2026; doi:10.1038/s42255-026-01643-4In a double-blind, placebo-controlled trial, intermittent dasatinib and quercetin treatment over 21 weeks improves liver fibrosis in patients with MASH, as shown by paired liver biopsies, and reduces senescence and fibrotic gene signatures, as demonstrated by single-nucleus transcriptomics.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itInhibiting fructose metabolism to treat fatty liverNature Metabolism, Published online: 07 October 2026; doi:10.1038/s42255-026-01627-4In this issue of Nature Metabolism, Koene et al. present evidence that inhibiting fructose metabolism (using a ketohexokinase inhibitor) can improve hepatic steatosis and insulin resistance in individuals who are prediabetic with obesity and metabolic dysfunction-associated steatotic liver disease, supporting further development and testing of fructose inhibitors in metabolic disease.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itMetabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trialNature Metabolism, Published online: 07 October 2026; doi:10.1038/s42255-026-01626-5In a randomized placebo-controlled crossover trial, pharmacological inhibition of ketohexokinase improved hepatic and systemic metabolic health in individuals with MASLD, highlighting fructose metabolism as a promising therapeutic target with benefits extending beyond the liver.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itArginine inhibits a key innate immune signalling hubNature Metabolism, Published online: 06 October 2026; doi:10.1038/s42255-026-01638-1The NLRP3 inflammasome has crucial roles in immunity and disease and is a key target for therapeutic efforts. In this issue of Nature Metabolism, Liu et al. show that l-arginine can inhibit inflammasome activation, highlighting the potential of dietary arginine supplementation as a treatment for NLRP3-related disease.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itMetabolic and neural responses to ultraprocessed foods: a randomized, controlled, crossover studyNature Metabolism, Published online: 05 October 2026; doi:10.1038/s42255-026-01619-4In a randomized study in 57 healthy-weight adults, researchers compared nutritionally matched ultraprocessed and non-ultraprocessed meals and found that ultraprocessed foods elicited greater insulin and energy responses, reduced carbohydrate oxidation and altered striatal brain activity linked to food reward despite similar subjective food value.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itSenolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trialNature Metabolism, Published online: 01 October 2026; doi:10.1038/s42255-026-01643-4In a double-blind, placebo-controlled trial, intermittent dasatinib and quercetin treatment over 21 weeks improves liver fibrosis in patients with MASH, as shown by paired liver biopsies, and reduces senescence and fibrotic gene signatures, as demonstrated by single-nucleus transcriptomics.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itmRNA methylation safeguards pancreatic α-cell identity against cellular plasticityNature Metabolism, Published online: 18 September 2026; doi:10.1038/s42255-026-01594-wThe epitranscriptomic mRNA modification N6-methyladenosine (m6A) helps to maintain the functional identity of pancreatic α-cells. Deletion of the m6A writer METTL14 impairs amino acid-stimulated glucagon secretion, destabilizes the α-cell state and promotes plasticity towards immature, insulin-secreting β-cell-like fates.
Nature Metabolism
@natmetabolism.nature.com
dlvr.itMeal timing as medicine: clinical evidence for intermittent fasting in Huntington’s diseaseNature Metabolism, Published online: 17 September 2026; doi:10.1038/s42255-026-01613-wIn a 12-week pilot study, 20 people with early-stage Huntington’s disease restricted their eating to a daily 6–8-h window. The intervention was feasible and well-tolerated, and exploratory analyses suggested improvements in clinical measures, levels of plasma neurofilament light (a biomarker of neurodegeneration) and cellular bioenergetics.